AU2017368901B2 - Calcium lactate compositions and methods of use - Google Patents

Calcium lactate compositions and methods of use Download PDF

Info

Publication number
AU2017368901B2
AU2017368901B2 AU2017368901A AU2017368901A AU2017368901B2 AU 2017368901 B2 AU2017368901 B2 AU 2017368901B2 AU 2017368901 A AU2017368901 A AU 2017368901A AU 2017368901 A AU2017368901 A AU 2017368901A AU 2017368901 B2 AU2017368901 B2 AU 2017368901B2
Authority
AU
Australia
Prior art keywords
acid
oil
calcium lactate
cancer
enteric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017368901A
Other languages
English (en)
Other versions
AU2017368901A1 (en
Inventor
Chong Hwan CHANG
Keun-Yeong JEONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metimedi Pharmaceuticals Co Ltd
Original Assignee
Metimedi Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metimedi Pharmaceuticals Co Ltd filed Critical Metimedi Pharmaceuticals Co Ltd
Publication of AU2017368901A1 publication Critical patent/AU2017368901A1/en
Priority to AU2023229549A priority Critical patent/AU2023229549A1/en
Application granted granted Critical
Publication of AU2017368901B2 publication Critical patent/AU2017368901B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A23L33/165—Complexes or chelates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/042—Lactic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/15—Inorganic Compounds
    • A23V2250/156—Mineral combination
    • A23V2250/1578—Calcium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017368901A 2016-11-30 2017-07-07 Calcium lactate compositions and methods of use Active AU2017368901B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023229549A AU2023229549A1 (en) 2016-11-30 2023-09-14 Calcium lactate compositions and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2016-0161931 2016-11-30
KR1020160161931A KR20180062063A (ko) 2016-11-30 2016-11-30 서방형 항암용 약학 조성물
PCT/IB2017/054091 WO2018100442A1 (en) 2016-11-30 2017-07-07 Calcium lactate compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023229549A Division AU2023229549A1 (en) 2016-11-30 2023-09-14 Calcium lactate compositions and methods of use

Publications (2)

Publication Number Publication Date
AU2017368901A1 AU2017368901A1 (en) 2019-06-13
AU2017368901B2 true AU2017368901B2 (en) 2023-10-05

Family

ID=62242802

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017368901A Active AU2017368901B2 (en) 2016-11-30 2017-07-07 Calcium lactate compositions and methods of use
AU2023229549A Abandoned AU2023229549A1 (en) 2016-11-30 2023-09-14 Calcium lactate compositions and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023229549A Abandoned AU2023229549A1 (en) 2016-11-30 2023-09-14 Calcium lactate compositions and methods of use

Country Status (12)

Country Link
US (3) US11285121B2 (https=)
EP (1) EP3547999A4 (https=)
JP (1) JP2020500870A (https=)
KR (3) KR20180062063A (https=)
CN (2) CN110087632B (https=)
AR (1) AR110302A1 (https=)
AU (2) AU2017368901B2 (https=)
MX (1) MX2019006291A (https=)
MY (1) MY206468A (https=)
PH (1) PH12019501199A1 (https=)
TW (2) TWI827535B (https=)
WO (1) WO2018100442A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019138379A1 (en) 2018-01-12 2019-07-18 Metimedi Pharmaceuticals Co., Ltd. Methods of treating chronic inflammatory diseases
CN112512406A (zh) * 2018-06-06 2021-03-16 梅西莫股份有限公司 阿片类药物过量监测
US12097043B2 (en) 2018-06-06 2024-09-24 Masimo Corporation Locating a locally stored medication
KR101998246B1 (ko) * 2018-08-22 2019-07-10 주식회사 메타파인즈 금속이온에 결합된 이온화합물을 포함하는 암 치료용 약학 조성물
US11464410B2 (en) 2018-10-12 2022-10-11 Masimo Corporation Medical systems and methods
DK3980001T3 (da) * 2019-06-10 2025-12-01 Ponce De Leon Health Designated Activity Company Depotsammensætninger af alfa-ketoglutarat
EP4093507A4 (en) * 2020-01-24 2024-02-28 Barkey, Daniel, Q. WEIGHT LOSS COMPOSITIONS AND METHODS
WO2021188999A2 (en) 2020-03-20 2021-09-23 Masimo Corporation Health monitoring system for limiting the spread of an infection in an organization
CA3187241A1 (en) * 2020-08-03 2022-02-10 Krishna Murthy Bhavanasi Pharmaceutical compositions comprising ribociclib
KR102840190B1 (ko) * 2022-04-19 2025-07-29 (의) 삼성의료재단 생리활성물질 전달체
WO2024242545A1 (ko) * 2023-05-23 2024-11-28 (주) 메티메디제약 칼슘 락테이트를 활성 성분으로 포함하는 암 백신 조성물 및 그 용도
EP4502147A1 (en) 2023-07-31 2025-02-05 M2Rlab SL Method for the polarization of cells to a new m2 phenotype and uses of said m2-polarized cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980951A (en) * 1996-04-10 1999-11-09 Merck & Co., Inc. Oral coated active drugs
CN102823872A (zh) * 2012-08-22 2012-12-19 安徽泰格生物技术股份有限公司 包膜乳酸钙颗粒及其制备方法
EP2599477A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
WO2015177329A1 (en) * 2014-05-23 2015-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a patient will achieve a response after radiation therapy
CA2972610A1 (en) * 2014-12-29 2016-07-07 Metimedi Pharmaceuticals Co., Ltd. Pharmaceutical composition for treating cancer comprising metal lactate salt

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279997A (en) * 1963-10-22 1966-10-18 Herbert D Schneyer Enteric coated calcium lactate tablets containing an antihistamine and thiamine chloride
JPS4837815B1 (https=) * 1970-09-25 1973-11-14 Yamanouchi Pharma Co Ltd
DE68905424T2 (de) * 1988-08-22 1993-06-24 Takeda Chemical Industries Ltd Alpha-glucosidaseinhibitor zur foerderung der calciumabsorption.
DE10233229A1 (de) * 2002-07-22 2004-02-12 S.K. Enterprise Gmbh Pharmazeutische Zusammensetzung zur Senkung des Triglyceridspiegels
US20060118003A1 (en) * 2002-12-17 2006-06-08 Yukoh Sakata Light-blocking agent and film-forming composition
ES2255429B1 (es) * 2004-10-25 2007-08-16 Italfarmaco, S.A. Composiciones farmaceuticas bucodispersables.
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
CN1961957A (zh) * 2005-11-09 2007-05-16 天津市礼人医药科技有限公司 一种抗衰老结肠吸收制剂
UA95093C2 (uk) 2005-12-07 2011-07-11 Нікомед Фарма Ас Спосіб одержання кальцієвмісної сполуки
US20070196399A1 (en) 2006-02-21 2007-08-23 Shin-Etsu Chemical Co., Ltd. Enteric-coated preparation covered with enteric coating material for site-specific delivery of drug to site within the small intestine
JP2008044927A (ja) * 2006-02-21 2008-02-28 Shin Etsu Chem Co Ltd 小腸内部位特異的薬物デリバリーのための腸溶性コーティング基剤で被覆した腸溶性製剤
EP2114380A1 (en) * 2007-01-25 2009-11-11 Panacea Biotec Ltd. Modified release pharmaceutical composition and a process of making the same
CN101139281A (zh) * 2007-10-16 2008-03-12 陈杰 纳米乳酸钙及其制备方法
CN101385696B (zh) * 2008-07-29 2012-01-04 北京圣医耀科技发展有限责任公司 含依托泊苷的海藻酸钠微球血管栓塞剂及制备方法与用途
CA2754684A1 (en) 2009-03-26 2010-09-30 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
US8247000B2 (en) * 2009-04-10 2012-08-21 Cypress Pharmaceutical, Inc. Phosphate-binding magnesium salts and uses thereof
WO2014145219A1 (en) * 2013-03-15 2014-09-18 Cerolife Llc Orally administrable compositions comprising calcium
CN103316033B (zh) * 2013-07-03 2015-07-15 康晓飞 一种凝胶剂及其用途
CN104523612A (zh) * 2014-12-05 2015-04-22 海南卫康制药(潜山)有限公司 一种乳酸钙组合物咀嚼片及其制备方法
CN107898808B (zh) * 2017-10-31 2021-04-27 华仁药业股份有限公司 小儿用静脉营养制剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980951A (en) * 1996-04-10 1999-11-09 Merck & Co., Inc. Oral coated active drugs
EP2599477A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
CN102823872A (zh) * 2012-08-22 2012-12-19 安徽泰格生物技术股份有限公司 包膜乳酸钙颗粒及其制备方法
WO2015177329A1 (en) * 2014-05-23 2015-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a patient will achieve a response after radiation therapy
CA2972610A1 (en) * 2014-12-29 2016-07-07 Metimedi Pharmaceuticals Co., Ltd. Pharmaceutical composition for treating cancer comprising metal lactate salt

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JANG YEONG-SU ET AL: LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 147, 20 January 2016 (2016-01-20), pages 71 - 76, XP029422230, ISSN: 0024-3205, DOI: 10.1016/J.LFS.2016.01.030 *

Also Published As

Publication number Publication date
AU2017368901A1 (en) 2019-06-13
KR20230004968A (ko) 2023-01-06
CN110087632B (zh) 2023-09-19
US20220175706A1 (en) 2022-06-09
US20190307712A1 (en) 2019-10-10
EP3547999A1 (en) 2019-10-09
KR102512475B1 (ko) 2023-03-22
MX2019006291A (es) 2019-08-01
TWI841481B (zh) 2024-05-01
JP2020500870A (ja) 2020-01-16
TW202400132A (zh) 2024-01-01
KR20180062063A (ko) 2018-06-08
PH12019501199A1 (en) 2020-02-24
WO2018100442A1 (en) 2018-06-07
TW201821072A (zh) 2018-06-16
KR20190082949A (ko) 2019-07-10
CN110087632A (zh) 2019-08-02
US11285121B2 (en) 2022-03-29
MY206468A (en) 2024-12-18
AU2023229549A1 (en) 2023-09-28
CN117180249A (zh) 2023-12-08
US12059397B2 (en) 2024-08-13
EP3547999A4 (en) 2020-07-15
TWI827535B (zh) 2024-01-01
AR110302A1 (es) 2019-03-13
US20240350439A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
US12059397B2 (en) Calcium lactate compositions and methods of use
KR101943230B1 (ko) 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
JP5758003B2 (ja) 抗癌剤併用療法
US20240285640A1 (en) Combination therapy for treating pik3ca-mutated cancer
CN103370066B (zh) 用于治疗癌症的包含威罗菲尼和干扰素的组合疗法
US10695296B2 (en) Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredient
TW202227090A (zh) 四環喹諾酮類似物及其鹽類的藥物組合物
CN111565714B (zh) 包含依维莫司的实现稳定化的药剂学制剂
CA3153424A1 (en) Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof
HK40103513A (zh) 包含乳酸钙的药物组合物及其用途
HK40093376A (en) Combination therapy for treating pik3ca-mutated cancer
TW202517259A (zh) 溶出性及打錠性優異之製劑
HK1185808B (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)